Stearoyl-CoA desaturase (SCD1) converts saturated fatty acids into monounsaturated fatty acids.
Introduction:
In order to combat the rise in obesity and metabolic diseases, a large number of studies have attempted to define the etiology of impaired glucose metabolism, dyslipidemia, and lipodystrophy (1) (2) (3) (4) (5) . The results of these studies have generally shown that development of type 2 diabetes mellitus (T2DM) is dependent on a multitude of factors, including obesity due to overnutrition combined with physical inactivity, consumption of a high-fat/high-carbohydrate diet, and genetic predisposition (6) (7) (8) (9) . There have also been a number of studies designed to establish effective treatments and/or define drug targets to prolong the pre-diabetic state or to reduce the severity of established T2DM where a wide range of potential targets have been identified.
Despite the heterogeneity of causative factors leading to T2DM, there has been nearly unanimous agreement that impaired insulin signaling, increased intramuscular lipid deposition, and a loss of metabolic flexibility in skeletal muscle is critical for development of the disease (10;11).
The current study was intended to define the role of a key lipogenic enzyme, stearoylCoA desaturase-1 (SCD1), in regulating skeletal muscle lipid metabolism and how its overexpression can actually promote fat oxidation, exercise capacity, and glucose tolerance by increasing triglyceride synthesis. SCD1 is an integral membrane protein of the endoplasmic reticulum that catalyzes the desaturation of long chain saturated fatty acids (SFA) into monounsaturated fatty acids (MUFA). The enzyme is expressed in nearly all tissues of humans and mice where it converts primarily stearate (18:0) into oleate (18:1) and to a lesser extent palmitate (16:0) into palmitoleate (16:1) . Over the last 10+ years, a wealth of information has been collected to demonstrate that SCD1 knockout (KO) animals are completely resistant to the detrimental effects of high fat diets (12) (13) (14) (15) (16) (17) . Those animals retain insulin sensitivity, glucose by guest, on October 14, 2017 www.jlr.org Downloaded from tolerance, and lower body weight relative to wild-type (WT) counterparts due in large part to increased energy expenditure (18) . However, it is important to note that it is counterintuitive and unexpected that loss of SCD1 activity would actually protect from obesity and the related metabolic detriments. The increase in SFA content would be expected to increase inflammation, lipotoxicicty, and promote insulin resistance all leading to cardiovascular disease (CVD) (19;20) . However, we have recently shown that the anti-obesity phenotype in SCD1 null animals is due to loss of SCD1 in the skin (18) , which may be preventing the accumulation of SFA due to increased energy expenditure. In fact, recent studies examining the effect of tissue specific deletion of SCD1 in liver and adipose have shown no protection from obesity and may even increase inflammation when skin expression is normal (21-23).
In light of the results described above, we began to speculate that increased SCD1 activity, especially in skeletal muscle, may actually provide more protection from obesity and T2DM than SCD1 knockout or inhibition. This is because increased oleate synthesis or availability is known to increase DGAT-mediated triglyceride (TG) synthesis at the expense of diacylglycerol (DAG) and free fatty acids (FFA) (24). Sequestering FFA and DAG into TG has been shown to increase insulin sensitivity and increase metabolic flexibility (25). Thus, by increasing MUFA production at the expense of SFA in skeletal muscle, we clearly demonstrate that increased SCD1 expression in the skeletal muscle can increase muscle TG synthesis, glucose uptake, and PPARδ expression. Furthermore, SCD1 overexpressing mice increase exercise capacity by more than 2-fold.
Methods:
Animals, diets, and tissue collection: We generated the muscle specific SCD1 overexpressing mouse using the human skeletal muscle α-actin promoter (26) coupled with mouse SCD1 (actin by guest, on October 14, 2017 www.jlr.org Downloaded from SCD1-Tg). Animals on a mixed FVB/C57Bl/6J background were backcrossed 10 generations to C57Bl/6J animals. Genotyping was performed by routine PCR of genomic tail DNA. Male mice were weaned at 3 weeks of age and then individually caged at 8 weeks of age and fed a standard chow diet (Purina Formulab 5008). All aspects of the study were approved by the Animal Care and Use Committees of the University of Wisconsin-Madison and Texas Tech University.
Microsomes and mouse SCD1 western blots were prepared as previously described (18) .
Quantification of gene expression: mRNA was extracted from tissues and cells using Tri Reagent (Molecular Research Center, Cincinnati, OH) and reverse transcribed using AB high capacity cDNA synthesis kits (Applied Biosystems). Quantification of changes in target gene expression was performed using quantitative real-time PCR with an Eppendorf Realplex 2 and SYBR green master mix (Invitrogen) using β-actin as the reference gene. PCR primers (Integrated DNA Technologies, Coralville, IA) were designed to span exon-exon boundaries to prevent amplification of genomic DNA and all PCR products were confirmed using dissociation curve analysis and visualized by running on an EtBr stained 2% agarose gel.
Glucose tolerance tests. Mice were fasted for four hours in the early light cycle prior to collecting a basal blood sample by retro-orbital puncture. Mice were then given an intraperitoneal (IP) injection of glucose solution (1 gram glucose/kg body weight) and blood samples were collected 10, 20, 40, 80, and 120 minutes post-injection. Blood was collected into EDTA and glucose measured using a glucose oxidase colorimetric assay. methylated, and analyzed by gas-liquid chromatography to determine fatty acid composition as previously described (18) . For exercised mice, total lipids were extracted and directly methylated prior to GC analysis. Total muscle TG's were determined using an enzymatic assay (Wako Chemicals).
Tissue mitochondrial isolation: Mitochondria (mt) and mtDNA were isolated essentially as described (28). Briefly, approximately 30 mg of tissue was homogenized with 100 µl of the homogenate retained for analysis of total protein using the Bradford assay. The remaining homogenate as mitochondrial protein isolate. From the remaining isolated mitochondrial protein, mitochondria DNA was isolated and measured using a spectrophotometer prior to assay use or storage at -20° C.
Exercise testing: Grip time was assessed by placing animals on the top of the wire cage lids and inverting them. The time to fatigue was determined at the point in which the animals could no long maintain their grip. Swim time to exhaustion was assessed by placing animals in 2000 ml glass beakers filled with 30°C water and monitoring the length of time until the animals were no longer able to maintain their head (nose) above the water. Voluntary free-wheel running activity was measured over the course of 5 days in the dark cycle. Free-wheel revolutions were counted using the home cage wheel counter software (Columbus Instruments, Columbus, OH were performed at least three times.
Results:
We have generated mice that overexpress mouse SCD1 in skeletal and cardiac muscle under the control of the human α-actin promoter (26). Four founders were identified that carried the SCD1 transgene ( Figure 1A) ; line 282 displayed the highest SCD activity and was selected for backcrossing. These mice display ~10-fold higher muscle SCD1 mRNA in soleus and gastrocnemius (gastroc) muscle ( Figure 1B ) while brain, small intestine, liver, and lung remain unchanged. Diaphragm muscle SCD1 mRNA expression was increased over 3,000-fold in the Tg mice ( Figure 1C ). We are uncertain as to why this muscle tissue was increased to such an extent, however it is possible that its uniform composition (e.g. nearly 100% type I oxidative fibers), or the fact that it is a highly active muscle tissue even in sedentary mice could cause SCD1 mRNA overexpression to persist at greater levels compared to other muscle tissues.
Microsomes obtained from mixed gastroc muscle displayed ~10-fold higher SCD1 protein content ( Figure 1D ).
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Actin-SCD1 Tg animals breed normally with expected litter sizes (data not shown) and aside from a slightly reduced body weight ( Figure 1E ), are indistinguishable from their WT counterparts. Despite no significant difference in SCD1 expression in the heart, gross assessment of the cardiac muscle displays a slight but non-significant increase in heart weight that becomes significant after 4 weeks of exercise training (WT = 5.4 ± 0.5 grams vs. SCD1-Tg = 6.3 ± 0.4 grams; p = 0.008) ( Figure 1F ). A number of factors could account for the difference in heart weight after exercise training (free wheel running) and could include increased TG and/or glycogen content, left ventricular hypertrophy, or a more generalized pathological or nonpathological enlargement of the heart. However, as the Actin SCD1-Tg animals run farther and longer than their WT counterparts (described in detail below), it is likely that exercise dosage is higher in the Tg group and likely eliminates pathological hypertrophy as the culprit.
To gain a better perspective of the physiological relevance of the degree to which SCD1 was increased in skeletal muscle, we provided WT C57Bl/6 mice with access to free-wheels for more than two-fold higher in the actin-SCD1 Tg mice thereby enhancing the % difference even more. Therefore, when taking into consideration the difference in total TG content, the differences between the individual FA species are actually 2-2.5-fold more pronounced. The changes in muscle lipid composition of SCD1 Tg mice were comparable to those seen in WT mice with exercise training in terms of DI and linoleic acid content further suggesting that the changes in transgenic overexpression are physiologically relevant (supplemental Figure 1A -B).
To determine if higher 18:2n6 levels in SCD1 Tg mice may lead to increased metabolism and/or food intake, we performed macronutrient and energy expenditure tests using metabolic cages. Additionally, we collected measures of food intake over two consecutive days in WT and SCD1 Tg counterparts. There were no differences in total energy expenditure as assessed by oxygen consumption but there were significant differences in RER and food intake (Supplemental Figure 2 A-I). Uncoupling is not measured via gas-exchange and may be higher in the SCD1 Tg mice since food intake is elevated (WT day 1 and 2: 3.9±0.3 and 3.6±0.1 grams/day vs. SCD1 Tg day 1 and day 2: 4.4±0.8 and 4.5±0.8 grams/day; p = 0.1 and 0.01 respectively) but body weight was lower ( Figure 1E ). Therefore, the increased TG 18:2n6 content may be due to hyperphagia and further detailed analyses of thermogenesis and uncoupling would be needed to conclusively determine if it in fact is occuring. RER, which is an indicator of fat vs. carbohydrate utilization, was higher in the fed sate (night cycle WT vs. SCD1
Tg Day 1 and 2, p < 0.0001) and lower in the fasted state (day cycle WT vs. SCD1 Tg Day 1 and 2, p < 0.0001). These data suggest that when glucose is present (fed state), the SCD1 Tg mice use more glucose and when animals are relying more on FFA in the fasted state, they preferentially use more fat for fuel.
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In addition to the fact that oleic acid has been shown to increase DGAT activity, it is also believed to increase SREBP-1c activation as well (34) . SREBP-1c is a transcription factor that regulates the expression of several genes involved in lipogenic activity as well as lipid processing and esterification. In order to help explain the increase in TG content of actin-SCD1
Tg muscles samples, we measured SREBP-1c gene expression along with the fatty acid elongase enzyme Elovl6 and the esterification enzyme DGAT2. In white gastroc, there was a significant increase in SREBP-1c but no difference in Elovl6 or DGAT2 between WT and actin-SCD1 Tg mice ( Figure 3A) . In red gastroc, SREBP-1c, Elovl6, and DGAT2 were all significantly elevated in the Tg animals ( Figure 3B ).
Increased muscle lipid content is thought to decrease insulin stimulated glucose uptake.
Therefore, in order to determine the effect of SCD1 overexpression on whole body glucose tolerance we assessed GLUT1 and GLUT4 mRNA expression, fasting blood glucose, and IP glucose tolerance (IP GTT). In both white ( Figure 4A ) and red (4B) gastroc, there was a significant increase in GLUT1 expression and in white gastroc, there was a significant decrease in GLUT4. GLUT1 is primarily responsible for non-insulin stimulated glucose uptake (basal) whereas GLUT4 is the insulin responsive glucose transported in skeletal muscle. It is unclear as to how SCD1 overexpression impacts GLUT1 and -4 expression, however it has been reported that long chain n-3 PUFA's increase GLUT1 expression (35) and oleate reduces GLUT4 expression (36) .
The GLUT expression patterns suggest altered glucose uptake, so to test this, we expressed the data as a percent change relative to fasting levels (i.e. normalized to the differences in fasting values), we saw that the pattern of change during the GTT was identical between WT and SCD1-Tg mice ( Figure 4D ). These data suggest that increased SCD1 activity and the resulting increased IMTG content do not negatively affect glucose uptake. In fact, it suggests that increased IMTG may actually enhance basal glucose disposal.
Saturated fat is thought to impair glucose uptake but with increased SCD1 activity, the SFA effect should be mitigated by the conversion to MUFA. We assessed the ability of ex vivo prepared muscle samples to transport 1mM 3 H labeled 2-deoxy-D-glucose (2-DG) in the presence or absence of insulin and/or 100μM palmitate (16:0). We used submaximal levels of insulin in order to observe differences between samples (maximal insulin stimulation might mask sub-maximal differences in sensitivity). As expected, we saw a significant increase in 2-DG uptake after insulin treatment in SCD1-Tg samples compared to WT (SCD1 Tg = 1.3 ± 0.08 vs.
WT = 1.1 ± 0.04 fold; p = 0.02) ( Figure 4E ). In the presence of 16:0, insulin stimulated 2-DG uptake was slightly depressed compared to basal levels in WT whereas SCD1 Tg was slightly but non-significantly elevated. The difference between the two though was significant (SCD1 Tg = 1.1 ± 0.06 vs. WT = 0.9 ± 0.04 fold; p = 0.03). Finally, insulin stimulated glucose uptake in the presence of palmitate was significantly depressed in WT and significantly elevated in SCD1 Tg samples (SCD1 Tg = 1.2 ± 0.06 vs. WT = 0.8 ± 0.02 fold; p = 0.0009). These data suggest that increased SCD1 activity can protect glucose uptake in the presence of elevated SFA.
In fact, these data suggest that increased IMTG may actually enhance insulin stimulated glucose disposal which is easily explained if it is considered that an increase in IMTG would occur alongside a decrease in FFA and DAG; both of which are thought to suppress insulin signaling more so than TG (37) .
Up-regulation of IMTG synthesis is also a well-known phenomenon of exercise training as a means to store lipid for metabolic energy in the form of TG. The animals in the current study were all untrained, yet we suspected that if IMTG levels were increased, then exercise capacity may be increased as a result due to increased local substrate/energy availability. We performed initial assessments of exercise capacity by testing grip strength ( Figure 5A ), swim time to exhaustion ( Figure 5B ), and daily free wheel running activity ( Figure 5C ). We noted that Figure 6A ). The purity of the mitochondrial fractions is confirmed in Figure 6B using the mitochondrial DNA specific primer sets for Cytochrome C oxidase subunit-1 (mtCo1), ctyochrome B (mtCytB), and the genomic DNA primer set for β-actin. The PCR successfully amplified mtCo1 and mtCytB DNA with no amplification of β-actin indicating that we had no contamination of genomic DNA in our mtDNA samples (with a β-actin positive control to demonstrate that the primer set works in the presence of genomic DNA).
The combined increase in mitochondrial content suggests that SCD1 overexpression in skeletal muscle may be sufficient to increase muscle fatty acid β-oxidation. To confirm this, we cultured skeletal muscle samples in HBSS and measured 14 C stearate (18:0) uptake ex vivo and the corresponding increase in 14 CO 2 formation produced as a result of labeled fatty acid β-oxidation. There was no difference in fatty acid uptake between WT and SCD1 Tg muscle samples indicating that entry into the cells was not different between genotypes ( Figure 6C ). Finally, we wanted to determine the mechanism by which SCD1 overexpression in skeletal muscle produced enhanced fatty acid oxidation. The most likely explanation for the metabolic phenotype is that a particular fatty acid species is acting as a ligand for PPARδ. This is based on the understanding that 1) PPARδ is the most abundant PPAR isoform in skeletal muscle (41), 2) that it is known to be activated by several fatty acids (42;43), and 3) overexpression of PPARδ in muscle was shown to increase metabolic function and exercise capacity in mice (38;40;44) . Therefore, we examined the effect of the three major fatty acid species identified from Figure 3C The changes in mRNA were matched by changes in PPARδ and Pgc-1 protein levels from cells that were treated with 18:2n6 from days 4-10 or from days 8-10 ( Figure 8F ). Further studies will need to examine the effect of 18:2n6 on skeletal muscle differentiation yet these data suggest that if the effect occurs in mature myocytes, then supplementation with linoleic acid may provide a means by which dietary lipid could increase metabolic and aerobic function in skeletal muscle.
Discussion:
Over the last 10-15 years, the majority of research regarding SCD1 has focused either on in vivo knockout (KO) models or in vitro models with suppression of desaturase activity. In KO models, there is a clear and consistent prevention of diet induced obesity (12;13;17;45-47) , yet investigators could not explain these results in light of the fact that insulin sensitivity was increased with a concomitant impairment in TG and/or MUFA synthesis. These paradoxical results have been largely ignored due to the overwhelming success of the SCD1 KO models in preventing obesity. However, recent work has shown clearly that despite its ability to prevent obesity, loss of SCD1 is associated with an increased risk for atherogenesis in SCD1 -/-x LDLR -/-double knockout animals (48;49). Furthermore, our previous work looking at skin specific deletion of SCD1 (SKO) (50) indicates that increased energy expenditure accounts for the anti- obesity effect and that increased β-oxidation likely prevents accumulation of toxic DAG and SFA. In other words, the detrimental effect of increased DAG and SFA is masked by increased energy expenditure from the skin defect in SKO or global KO animals. Therefore, only when SCD1 is removed from tissues other than skin can we see its detrimental effects on glucose metabolism or fatty acid uptake (13;22).
However, we have developed a model to increase MUFA synthesis specifically in skeletal muscle. It is quite likely that increasing the activity of SCD1 increases the rate of IMTG synthesis by increasing MUFA content of muscle which increases the rate of DGAT activity.
Increasing SCD1 activity promotes MUFA synthesis which is invariably incorporated into TG and appears to have a sparing effect on PUFA (50) . Increasing SCD1 activity also provides a better substrate for DGAT mediated TG synthesis thereby increasing the rate and efficiency of the reaction (24). The results of this model suggest that increased SCD1 activity in skeletal muscle increases glucose uptake, fatty acid oxidation, and exercise capacity. The mechanisms by which these increases are achieved are unlike those of the SCD1 KO models in which loss of SCD1 in the skin creates a hypermetabolic phenotype. Given the dramatic increases of PUFA content in the skeletal muscle of SCD1-Tg mice, we suspect the primary mechanism for the observed improved metabolic function in these animals is the result of increased availability of potential ligands for the transcription factor PPARδ and its subsequent activation.
Rather than simply increasing total energy expenditure, we suspect that the increased rate of MUFA production enables the sparing of n3 and n6 PUFA's. Several long chain PUFA's including linoleic acid (18:2n6) are known ligands of the transcription factor PPARδ and have been shown to increase its transcriptional activity (51;52). In our C2C12 cell culture model we were able to demonstrate the effect of 18:2n6 treatment on PPARδ and Cpt-1b expression.
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While there are a number of n3, n6, and even n9 PUFA's that are elevated in our model, we felt that 18:2n6 was the most likely candidate based on the absolute content compared to the other PUFA's in the TG fraction (18:2n6 ~20% vs. 18:3n3 ~ 0.2%, etc.). However, we also recognize that despite their ~100-fold lower concentration, some of the minor PUFA species may have much more potent bioactive effects than 18:2n6. Thus, it would be necessary to examine the effect of individual fatty acid species on regulating metabolic function through PPARδ. In order to achieve this, studies will need to be conducted in which specific PUFAs are removed from the diet to determine which species is responsible for the phenotype. Additionally, actin-SCD1 Tg mice on a muscle specific PPARδ null background should be used to determine if it mediates the increased metabolic effects. Lastly, while we suspect that the increased MUFA production observed in actin-SCD1 Tg mice results in increased PUFA sparing, the specific mechanism by which PUFAs accumulate in the skeletal muscle of these mice remains unknown and is a subject of further research.
Previous work has shown that overexpression of SCD1 in primary myocytes derived from lean humans suppressed fat oxidation (53) . This is in direct contrast to our results, however one major difference is that we saw an increase in PUFA content of muscle. It is somewhat surprising that muscle TG would contain significantly more PUFA when MUFA synthesis is increased. Although we only assessed TG fatty acid composition, it is expected that all neutral lipids in these samples would demonstrate a similar increase in PUFA content. Lastly, the WT and SCD1 Tg animals consumed the same diet leading us to conclude that the increase in TG PUFA's is due to 'sparing' of dietary sources.
We examined the role of SFA, MUFA, and PUFA on PPARδ and Cpt-1b expression in vitro and found that PUFA causes a significant increase in their expression. In the mouse model, Another aspect of increased skeletal muscle SCD1 activity is an increased exercise tolerance and capacity. Assessments of grip strength, swim time to exhaustion, voluntary freewheel running, and forced treadmill running all indicate that overexpression of SCD1 dramatically increases cardiovascular endurance. It was reported that DGAT1-Tg animals had decreased 24-hour activity and lower energy expenditure with no change in PPARδ expression (54), whereas our model indicates that PPARδ expression is increased >20-fold. We suspect that increased oleate synthesis is causing PUFA sparing which leads to enhanced PPARδ activity while DGAT1 activity would simply be passive in its role toward fatty acid composition. Narkar and colleagues developed a constitutively active PPARδ muscle transgenic model and they found that as a result, type I oxidative fiber content of muscle was increased (39) . This enabled the animals to withstand a greater workload of activity both before training and after treadmill exercise training. The authors also noted that SCD1 expression (which is a PPARδ target gene)
was elevated in the VP16-PPARδ model and we suspect that a similar phenomenon exists with The present data suggest that overexpression of SCD1, at least in muscle, provides a far greater benefit on metabolic function than does suppressing its activity. In fact, we hope these data will provide a paradigm shift that will re-examine the notion that suppressing either SCD1
or DGAT activity by pharmacological means may not provide the most ideal phenotype.
Instead, nutritional and/or lifestyle interventions aimed at increasing muscle SCD1 activity and PUFA content should be strongly considered. If enhanced SCD1 activity in skeletal muscle is sufficient to decrease fasting glucose, while increasing fat oxidation, and exercise capacity, then means to suppress its activity should be avoided or at least used with caution. Instead, it may prove to be more efficacious to use dietary supplementation of PUFA either alone or in combination with aerobic exercise training to increase overall metabolic health. Forced exercise capacity was determined by treadmill running at 18m/min (D). WT mice ran for 6.6 ± 3.8 min and the Tg mice continued to run for 71.9 ± 9.5 min (p = 0.0008). Individual scores for each mouse is illustrated in (E) and shows that all WT mice ran for less time than all Tg animals (WT n = 4; Tg n = 5). *p < 0.05 between WT and SCD1 Tg. 
